Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 22;8(46):81636-81648.
doi: 10.18632/oncotarget.20386. eCollection 2017 Oct 6.

Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer

Jiantang Zhang #  1 , Fangmeng Fu #  1 , Yuxiang Lin #  1 , Yazhen Chen  1 , Minjun Lu  1 , Minyan Chen  1 , Peidong Yang  1 , Meng Huang  2 , Chuan Wang  1
Affiliations
Free PMC article
Review

Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer

Jiantang Zhang et al. Oncotarget. .
Free PMC article

Abstract

Capecitabine in addition to anthracycline-taxane based regimens for patients with early breast cancer (EBC) has been reported in previous clinical trials, but the reported efficacy of this regimen remained inconsistent. In order to clarify the survival benefit of this regimen, a meta-analysis was performed. The systematic literature search was conducted in PubMed, the Cochrane library and Google scholar. The hazard ratios (HRs) were used to evaluate the efficacy and adverse events. The result indicated that capecitabine combine with an anthracycline-taxane based regimen would significantly improve DFS (HR = 0.87, 95% CI 0.77-0.97) and OS (HR = 0.78, 95% CI 0.66-0.91) compared with the controls. In subgroup analysis, we found that capecitabine improved the DFS in hormone receptor negative (HR = 0.72, 95% CI 0.53-0.92) and triple negative (HR = 0.67, 95% CI 0.49-0.86) EBC patients. However, adding capecitabine might also increase the occurrence of some side-effects, such as hand-foot syndrome, stomatitis and diarrhea. Capecitabine combined with an anthracycline-taxane based regimen maybe effective and well-tolerated by patients with EBC, especially for triple negative breast cancer, and might be a good clinical choice.

Keywords: capecitabine; disease-free survival; early breast cancer; overall survival; side-effects.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1. Process of studies selection
Figure 2
Figure 2. Forest plot showing the difference of total DFS in using capecitabine or not
Figure 3
Figure 3. Forest plot showing the difference of total OS in using capecitabine or not
Figure 4
Figure 4. Forest plot of RFS in using capecitabine or not
Figure 5
Figure 5. Forest plot of the pCR for the addition of capecitabine or not
Figure 6
Figure 6. Forest plot of the subgroup DFS for the addition of capecitabine or not
Figure 7
Figure 7. Forest plot of the breast cancer specific survival for the addition of capecitabine or not
Figure 8
Figure 8. Forest plot of the adverse events for the addition of capecitabine or not
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136:E359–386. - PubMed
    1. Servick K. Breast cancer. Breast cancer: a world of differences. Science. 2014;343:1452–1453. - PubMed
    1. Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, Latreille J, Lemieux J, Provencher L, Verma S, Chia S, Wang B, Rayson D. Optimizing the management of HER2-positive early breast cancer: the clinical reality. Current Oncology. 2010;17:20–33. - PMC - PubMed
    1. Early Breast Cancer Trialists’ Collaborative G Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. - PubMed
    1. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;352:930–942. - PubMed

LinkOut - more resources